AnaptysBio (NASDAQ:ANAB) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of AnaptysBio (NASDAQ:ANAB) from a hold rating to a buy rating in a report released on Saturday.

Other equities research analysts have also issued reports about the company. Wells Fargo & Company upped their price target on AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. JPMorgan Chase & Co. upped their target price on AnaptysBio from $42.00 to $80.00 and gave the company an “overweight” rating in a report on Thursday, July 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, October 8th. UBS Group reissued a “neutral” rating and set a $20.00 price target (up previously from $18.00) on shares of AnaptysBio in a research report on Tuesday, August 12th. Finally, Wedbush raised their price objective on shares of AnaptysBio from $45.00 to $70.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $60.90.

AnaptysBio Stock Down 14.3%

Shares of ANAB opened at $33.98 on Friday. The firm’s fifty day moving average is $29.09 and its two-hundred day moving average is $24.83. The stock has a market cap of $940.91 million, a PE ratio of -12.05 and a beta of 0.16. AnaptysBio has a 52-week low of $12.21 and a 52-week high of $40.96.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, topping the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. The firm had revenue of $76.32 million for the quarter, compared to the consensus estimate of $15.83 million. As a group, research analysts anticipate that AnaptysBio will post -6.08 earnings per share for the current year.

Hedge Funds Weigh In On AnaptysBio

Large investors have recently made changes to their positions in the stock. First Light Asset Management LLC increased its holdings in AnaptysBio by 433.3% in the 1st quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company’s stock valued at $86,139,000 after purchasing an additional 3,764,720 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in shares of AnaptysBio by 4,852.7% during the third quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock worth $25,719,000 after buying an additional 822,975 shares during the period. Caption Management LLC grew its stake in shares of AnaptysBio by 106.3% in the first quarter. Caption Management LLC now owns 23,376 shares of the biotechnology company’s stock valued at $435,000 after buying an additional 394,634 shares in the last quarter. Woodline Partners LP raised its holdings in shares of AnaptysBio by 63.1% in the 1st quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock valued at $14,705,000 after buying an additional 305,950 shares during the period. Finally, 683 Capital Management LLC lifted its stake in AnaptysBio by 155.6% during the 2nd quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock worth $11,100,000 after acquiring an additional 304,373 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.